Abstract
The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Volume: 13 Issue: 2
Author(s): Ioannis Legakis and Konstantinos Syrigos
Affiliation:
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Abstract: The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Export Options
About this article
Cite this article as:
Legakis Ioannis and Syrigos Konstantinos, Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715303112129990027
DOI https://dx.doi.org/10.2174/18715303112129990027 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking and Virtual Screening to Identify PKC Agonists: Potentials in Anticancer Therapeutics
Current Computer-Aided Drug Design Haptotactic Gradients for Directed Cell Migration: Stimulation and Inhibition Using Soluble Factors
Combinatorial Chemistry & High Throughput Screening The Synthesis, Structural Study and Anticancer Activity Evaluation of Emodin Derivatives Containing Conjugative Groups
Medicinal Chemistry Research Advances on Anticancer Effect of Licorice
Current Bioactive Compounds miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Editorial (Thematic Issue: Cancer Biomarkers from Bench to Bedside)
Current Cancer Drug Targets Pathophysiological Implications of Dipeptidyl Peptidases
Current Protein & Peptide Science Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Improvement of Tumor Localization of Photosensitizers for Photodynamic Therapy and Its Application for Tumor Diagnosis
Current Topics in Medicinal Chemistry Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued) PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism